Biomea Fusion, Inc.
1.53%
1,060,792
1840439
09077A106
Oct 21, 2025
Oct 24, 2025, 04:10 PM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Chen Bihua | Individual | 1.53% | 1,060,792 | 110,792 | 950,000 |
| Cormorant Asset Management, LP | Partnership | 1.37% | 950,000 | 0 | 950,000 |
| Cormorant Global Healthcare Master Fund, LP | Partnership | 0.69% | 477,791 | 0 | 477,791 |
| Cormorant Global Healthcare GP, LLC | Other | 0.69% | 477,791 | 0 | 477,791 |
| Cormorant Private Healthcare Fund III LP | Partnership | 0.66% | 456,855 | 0 | 456,855 |
| Cormorant Private Healthcare GP III, LLC | Other | 0.66% | 456,855 | 0 | 456,855 |
Disclosure Items (3)
Common Stock
Biomea Fusion, Inc.
1599 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070
Cormorant Global Healthcare Master Fund, LP Cormorant Global Healthcare GP, LLC Cormorant Private Healthcare Fund III, LP Cormorant Private Healthcare GP III, LLC Cormorant Asset Management, LP Bihua Chen
200 Clarendon Street, 52nd Floor Boston, MA 02116
Cormorant Global Healthcare Master Fund, LP - Cayman Islands Cormorant Global Healthcare GP, LLC - Delaware Cormorant Private Healthcare Fund III, LP - Delaware Cormorant Private Healthcare GP III, LLC - Delaware Cormorant Asset Management, LP - Delaware Bihua Chen - United States
See Items 7-13 of the cover page and Item 2.
See Items 7-13 of the cover page and Item 2. The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon (i) a statement in a Prospectus filed by the Issuer on October 7, 2025 that there would be 69,322,377 shares of Common Stock outstanding following the closing of a public offering described therein, and (ii) a statement in a Current Report on Form 8-K filed by the Issuer on October 7, 2025 reporting that the public offering was expected to close on October 8, 2025. The shares reported for Bihua Chen reflect shares of Common Stock that she has the right to receive within 60 days upon the exercise of stock options granted to her in her capacity as a director of the Issuer.
The Reporting Persons effected the following transactions in the Company's Common Stock in the 60 day period beginning on the date requiring the filing of this Schedule 13D: (i) on October 22, 2025, the Reporting Persons sold an aggregate of 820,872 shares of Common Stock in open-market transactions at prices ranging from $1.42 to $1.58 per share (weighted-average price $1.48 per share); and (ii) on October 23, 2025, the Reporting Persons sold an aggregate of 1,800,000 shares of Common Stock in open-market transactions at prices ranging from $1.35 to $1.51 per share (weighted-average price $1.41 per share). The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price of the transactions reported in this Schedule 13D.
Not applicable.
As a result of the transactions described herein, as of October 22, 2025, the Reporting Persons ceased to be the beneficial owners of more than five percent of the Issuer's outstanding Common Stock.